Hong In Yoon
연세대학교 의과대학 내과학과 · 의학
홍인윤 교수의 연구실은 종양학 및 방사선 옹생학 분야에서 활발한 연구를 수행하고 있습니다. 특히 자궁경부암, 간세포암, 뇌간신경아교종, 직장암 등 다양한 종류의 암에서 방사선 치료의 효과성과 부작용 예측에 중점을 두고 있으며, 특히 방사선 간손상 예측, 병변의 정밀 세그멘테이션, 치료 계획 최적화 등 첨단 영상 및 딥러닝 기반 기술을 융합한 연구를 진행하고 있습니다. 환자 중심의 개인화된 치료 전략 수립을 목표로, 임상적 실용성과 과학적 정밀도를 동시에 추구합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Our institutional experiences showed that EFRT was an effective treatment for cervical cancer patients with PAN metastasis. The addition of chemotherapy to EFRT seems to have uncertain survival benefit with higher hematologic toxicity.
These results suggest that pre-RT ICG-R15 could be a useful factor in predicting radiation hepatotoxicity in HCC patients treated with RT.
The detection of H3K27M mutation is the most important diagnostic criteria for DMG. Combination of surgery (if amenable to surgery), radiotherapy, and chemotherapy based on comprehensive multidisciplinary discussion can be considered as the treatment options for DMG.
These findings demonstrated that a strong possibility that upfront chemotherapy and short-course RT with delayed surgery are an effective alternative treatment for LARC with potentially resectable distant metastasis, owing to achievement of pathologic down-staging, R0 resection, and favorable compliance and toxicity, despite the long treatment duration.
Our findings show that bladder volume could be maintained more consistently during RT by protocol-based management using a bladder scan.
Recently, several efforts have been made to develop the deep learning (DL) algorithms for automatic detection and segmentation of brain metastases (BM). In this study, we developed an advanced DL model to BM detection and segmentation, especially for small-volume BM. From the institutional cancer registry, contrast-enhanced magnetic resonance images of 65 patients and 603 BM were collected to train and evaluate our DL model. Of the 65 patients, 12 patients with 58 BM were assigned to test-set fo
RT-involving multimodality treatments can enhance the overall therapeutic successes for advanced liver-confined HCC and also provide potential cures to some patients via conversion to a resectable condition.